Protocol Ledger

NCT06541704 · Phase III · RECRUITING

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Interventional Phase III clinical trial protocol NCT06541704 sponsored by Regeneron Pharmaceuticals in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-30 Enrollment: 975 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06541704
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)975 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06541704
Protocol FieldVerified Registry Value
NCT IdentifierNCT06541704
Consolidated Lead SponsorRegeneron Pharmaceuticals
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment975 participants (ESTIMATED)
Registered Start Date2024-10-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06541704
Hospital Research SiteLocationSite Profile
Retina Vitreous Associates Medical GroupBeverly Hills, CAOpen Hospital Dossier ->
The Retina PartnersEncino, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI